Completed PHASE1 INTERVENTIONAL 1-arm NCT02661685

Safety Study of Adoptive Transfer of Autologous IKDC-like Cells

An Immunotherapy for Metastatic Cancer Patients by Adoptive Transfer of Autologous IKDC-like Cells - Phase 1 Clinical Trial

Sponsor: Academia Sinica, Taiwan

Conditions Neoplasm Metastasis

Interventions autologous IKDC-like cells

Updated 9 times since 2017 Last updated: Feb 17, 2021 Started: May 31, 2016 Primary completion: Oct 31, 2019 Completion: Oct 31, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Neoplasm Metastasis, this trial is completed. The trial is conducted by Academia Sinica, Taiwan and has accumulated 9 data snapshots since 2016. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Mar 2021 — Jul 2024 [monthly]

Completed PHASE1

Status: Active Not Recruiting → Completed
Jan 2021 — Mar 2021 [monthly]

Active Not Recruiting PHASE1
Apr 2019 — Jan 2021 [monthly]

Active Not Recruiting PHASE1

Status: Recruiting → Active Not Recruiting

▶ Show 4 earlier versions

Sep 2018 — Apr 2019 [monthly]

Recruiting PHASE1
Jun 2018 — Sep 2018 [monthly]

Recruiting PHASE1
Apr 2017 — Jun 2018 [monthly]

Recruiting PHASE1
Jan 2017 — Apr 2017 [monthly]

Recruiting PHASE1

First recorded

May 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Academia Sinica, Taiwan
Ministry of Science and Technology, Taiwan
National Defense Medical Center, Taiwan

Data source: National Defense Medical Center, Taiwan

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Taipei, Taiwan